The Council for Responsible Nutrition on Monday praised the U.S. House of Representatives for its passage of the Designer Anabolic Steroid Control Act of 2014 (H.R. 4771), introduced by Reps. Joe Pitts, R-Pa., and Frank Pallone, D-N.J.
Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global.
The National Association of Chain Drug Stores has announced that NACDS-backed bipartisan legislation, H.R. 4190, which would expand pharmacists’ ability to serve patients and improve their healthcare outcomes, has garnered a milestone 100 co-sponsors.
The Food and Drug Administration recently announced the availability of the “Purple Book,” which lists biological products in much the same way that the "Orange Book" lists pharmaceuticals.
America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention.
Silvergate Pharmaceuticals on Monday announced that the Food and Drug Administration approved Epaned (enalapril maleate Powder for oral solution) for the treatment of symptomatic heart failure, as well as the treatment of asymptomatic left ventricular dysfunction.
Mylan is now free to resume distribution of its generic Precedex product (dexmedetomidine hydrochloride injection) to customers, effective immediately.
The Council for Responsible Nutrition on Friday asked that the Center for Nutrition Policy and Promotion recommend that consumers supplement their healthy diet with a multivitamin.
The number of uninsured is expected to decline by nearly half from 45 million in 2012 to 23 million by 2023 as a result of the coverage expansions associated with the Affordable Care Act.
Merck on Thursday announced that the Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma.